Publication Name	World Journal of Gastrointestinal Pathophysiology
Manuscript ID	22813
Country	Canada

Received	2015-09-25 14:21
Peer-Review Started
To Make the First Decision
Return for Revision
Revised
Second Decision	2015-09-28 08:23
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-09-28 08:25
Articles in Press	2015-09-28 08:25
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-11-03 18:22
Publish the Manuscript Online	2015-11-17 12:17

ISSN	2150-5330 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pathology
Manuscript Type	Review
Article Title	Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders
Manuscript Source	Unsolicited Manuscript
All Author List	Grace Y Lam, Brendan P Halloran, Anthea C Peters and Richard N Fedorak
Funding Agency and Grant Number
Corresponding Author	Dr. Brendan P Halloran, Department of Medicine, Division of Gastroenterology, University of Alberta, Zeidler Ledcor Centre, 130 University Campus NW, 8440 112 St NW Edmonton, Alberta, Canada. brendan@ualberta.ca
Key Words	Epstein-Barr virus; Immunosuppression; Post-transplantation lymphoproliferative disorders; Lymphoproliferative disorders; Inflammatory bowel disease
Core Tip	Immunosuppressive agents, such as thiopu-rines, methotrexate, and biologics, have revolutionized the treatment and maintenance therapy of inflammatory bowel disease (IBD). However, their use may come at the cost of increased risk of developing lym-phoproliferative disorders (LPD). While little is known about this risk in IBD, more is known about immuno-suppression risk in the fields of rheumatoid arthritis and post-transplantation with regards to the development of Epstein-Barr virus (EBV) associated LPD. Here, we attempt to review lymphoma risk in the setting of immunosuppression use in various medical conditions, discuss what lessons may be translatable to the IBD field and what future directions can be taken to reduce the risk of EBV-associated LPD from immunosuppression use in IBD.
Publish Date	2015-11-17 12:17
Citation	Lam GY, Halloran BP, Peters AC, Fedorak RN. Lympho­proliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. World J Gastrointest Pathophysiol 2015; 6(4): 181-192
URL	http://www.wjgnet.com/2150-5330/full/v6/i4/181.htm
DOI	http://dx.doi.org/10.4291/wjgp.v6.i4.181

Full Article (PDF)	WJGP-6-181.pdf
Full Article (Word)	WJGP-6-181.doc
Manuscript File	22813-Review.docx
Answering Reviewers	22813-Answering reviewers.pdf
Audio Core Tip	22813-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	22813-Conflict-of-interest statement.pdf
Copyright License Agreement	22813-Copyright assignment.pdf
Peer-review Report	22813-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	22813-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	22813-Scientific misconduct check.pdf
Scientific Editor Work List	22813-Scientific editor work list.pdf